Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of GM-60106 in healthy adults and adults with NAFLD markers
NCT05517564Phase 1Unknown
- Sponsor
- JD Bioscience
- Start
- Aug 2022
- Primary completion
- Feb 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GM-60106 in Nonalcoholic steatohepatitis (NASH) (6 arms), sponsored by JD Bioscience. Primary endpoint: Incidence, nature, and severity of adverse events up to 63 days. Status: unknown.
02
Drugs
GM-60106
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05517564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517564.